GlassScriptPhysician profile
Ria Alexander
NPI 1700422979
$3,625.21
in general payments reported to CMS, 2019-2025
44 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,835 · 2022: $522 · 2023: $219 · 2024: $654 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Consulting Fee: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.28 |
| Consulting Fee | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $448.00 | 2021-2025 | Lynparza, Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $324.26 | 2021-2023 | Imbruvica |
| Amgen INC. | $300.31 | 2021-2022 | |
| Incyte Corporation | $254.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $210.53 | 2021-2022 | |
| Daiichi Sankyo INC. | $188.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $162.31 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.47 | 2021-2025 | Gammagard |
| Seagen INC. | $148.31 | 2021 | |
| Abbvie INC. | $123.97 | 2024 | |
| Genzyme Corporation | $82.42 | 2021 | |
| Glaxosmithkline, LLC. | $74.22 | 2021-2023 | Jemperli, Zejula |
| Morphosys, US INC. | $74.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $72.78 | 2021-2025 | Welireg, Keytruda |
| Jazz Pharmaceuticals INC. | $71.92 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $60.99 | 2021-2025 | Tukysa, Braftovi, Mektovi |
| Argenx US, INC. | $60.73 | 2023-2024 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $53.30 | 2021 | |
| Janssen Biotech, INC. | $51.03 | 2021-2025 | Akeega, Erleada |
| Beone Medicines USA, INC. | $49.72 | 2025 | Brukinsa |
| Epizyme, INC. | $47.07 | 2021-2022 | |
| Exelixis INC. | $45.97 | 2024-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $44.21 | 2022-2023 | Soliris |
| Genentech USA, INC. | $42.36 | 2021-2025 | Venclexta |
| Eisai INC. | $37.61 | 2021-2024 | |
| Immunocore Limited | $33.37 | 2023-2024 | Kimmtrak |
| Gilead Sciences, INC. | $32.93 | 2025 | Trodelvy |
| Caris Mpi, INC. | $32.60 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $31.60 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $30.51 | 2024 | Monoferric |
| Tersera Therapeutics LLC | $28.79 | 2021 | |
| Coherus Oncology, INC. | $25.94 | 2023 | |
| Pfizer INC. | $25.22 | 2021-2022 | |
| Legend Biotech USA INC. | $24.82 | 2025 | Carvykti |
| Sobi, INC | $22.26 | 2025 | |
| Melinta Therapeutics, LLC | $20.88 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Myovant Sciences INC. | $19.69 | 2021 | |
| Organon LLC | $19.64 | 2023 | Ontruzant, Renflexis |
| Beigene USA, INC. | $19.57 | 2021 | |
| Boston Scientific Corporation | $16.93 | 2021 | |
| Eusa Pharma (US) LLC | $16.86 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.95 | 2021 | |
| Lilly USA, LLC | $14.51 | 2021 | |
| Celgene Corporation | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ria Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.